Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
152 hedge funds and large institutions have $623M invested in Mersana Therapeutics in 2022 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 61 increasing their positions, 27 reducing their positions, and 14 closing their positions.
1,089% more call options, than puts
Call options by funds: $107K | Put options by funds: $9K
186% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 14
126% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 27
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
53% more capital invested
Capital invested by funds: $408M → $623M (+$215M)
21% more funds holding
Funds holding: 126 → 152 (+26)
0.15% more ownership
Funds ownership: 3.64% → 3.8% (+0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$15.9M |
| 2 |
ABG
Ally Bridge Group
New York
|
+$6.06M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$5.38M |
| 4 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$4.49M |
| 5 |
D.E. Shaw & Co
New York
|
+$4.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$14.6M |
| 2 |
BlackRock
New York
|
-$11.7M |
| 3 |
Millennium Management
New York
|
-$3.89M |
| 4 |
JP Morgan Chase
New York
|
-$2.54M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.31M |
MRSN Hedge Fund Activity: Q3 2022 in Review
152 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q3 2022, worth a combined $623M — up 53% from $408M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new MRSN positions and 14 closed out — a net gain of 26 holders — while 61 added to existing stakes and 27 trimmed.
The largest buyer was State Street, adding an estimated $15.9M. The largest seller was Woodline Partners, exiting entirely with an estimated $14.6M sold.
- 152 institutional investors held Mersana Therapeutics (MRSN) as of Q3 2022, up from 126 in Q2 2022.
- Funds reported $623M of Mersana Therapeutics stock for Q3 2022, up 53% quarter-over-quarter.
- 40 funds opened new Mersana Therapeutics positions in Q3 2022 and 14 closed out, a net change of +26 holders.
- The largest Mersana Therapeutics buyer in Q3 2022 was State Street, an estimated $15.9M added.
- The largest Mersana Therapeutics seller in Q3 2022 was Woodline Partners, an estimated $14.6M sold.
Based on aggregated 13F filings for Q3 2022.